

05-16-07

PCT

IAP12 Rec'd PCT/PTO 14 MAY 2007



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Richard K. Cooper

Serial No. **10/583,812**

Filing Date: **June 22, 2006**

For: **Gene Therapy Using Transposon Based Vectors**

Art Unit: **1632**

Examiner: **Anoop K. Singh**


**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In response to the Notification to Comply dated March 12, 2007, applicants submit herewith an initial diskette which contains the computer readable form (CRF) of the Sequence Listing shown on the paper copy. The CRF Sequence Listing is identical to the paper copy filed concomitantly and contains no new matter. Pursuant to 37 C.F.R. § 1.821(e), the paper copy and the computer readable form of the Sequence Listing are the same. This sequence listing is identical to the sequence listing filed in the PCT application PCT/US2004/043092, except that SEQ ID No: 10 has no sequence associated with it as SEQ ID No: 10, as filed in the PCT case, was duplicated as SEQ ID No: 16. The specification of the present case was already amended

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on May 14, 2007.


John K. McDonald, Ph.D. - Reg. No. 42,860

to delete the number 10 as a SEQ ID No: in a preliminary amendment filed June 22, 2006 (page 3 of that preliminary amendment). Accordingly, no new matter is included.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'J. K. McDonald', written over the printed name.

By: John K. McDonald, Ph.D.
Reg. No. 42,860

KILPATRICK STOCKTON LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309
Telephone: (404) 815-6500
Our Docket: 51687-331126



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/583,812	Richard K. Cooper	51687-0261 (331126)

23370
 JOHN S. PRATT, ESQ
 KILPATRICK STOCKTON, LLP
 1100 PEACHTREE STREET
 ATLANTA, GA 30309

INTERNATIONAL APPLICATION NO.

PCT/US04/43092

I.A. FILING DATE

PRIORITY DATE

12/24/2004

12/24/2003

CONFIRMATION NO. 4921

371 FORMALITIES LETTER



OC000000022814194

Date Mailed: 03/12/2007

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or

RCVD MAR 15 '07

visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

PATRICIA A BOOKER

Telephone: (703) 308-9140 EXT 204

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/583,812	PCT/US04/43092	51687-0261 (331126)

FORM PCT/DO/EO/922 (371 Formalities Notice)